Mark Hahn is the founder of Verona Pharma. Verona Pharma has raised $600M in total funding. Latest round: IPO. Backed by Oaktree, OMERS.
Mark W. Hahn served as Chief Financial Officer of Verona Pharma PLC from March 2020 until its acquisition. Previously, he was CFO of Dova Pharmaceuticals and Cempra, Inc., leading capital raises, product launches, and an IPO. He began his career at Ernst & Young and holds a BBA in Accounting and Finance.
Full founder directory · Investor directory · Company funding database · Fundraising library